CADL
Candel Therapeutics, Inc.
$7.93
+2.85%
$564.9M
No data for this timeframe.
Vol
Market Cap$564.9M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (87%)
Inst. Holders7 funds
Inst. Value$62.3M
Inst. Activity2 buys / 1 sells
Insider Activity1B / 0S
Insider Net $$3.0M
Reddit Sentiment64° Warm
SEC Reports3
Press Releases5
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001841387·Prev Close $7.71
Recent Activity
May 15, 2026
Press
Candel Therapeutics announced extended follow-up data from the phase 3 trial of aglatimagene (CAN-2409) in localized pro
Impact 8/10
May 15, 2026
fda
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
<p align="justify">NEEDHAM, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Can
May 14, 2026
SEC
Candel Therapeutics reported Q1 2026 results: net loss of $8.9M vs net income of $7.4M in Q1 2025, driven by higher R&D
8-K — Impact 4/10
May 14, 2026
SEC
Candel Therapeutics reported Q1 2026 EPS of -$0.54, a 65.6% miss vs consensus of -$0.33, with no revenue. The company hi
PRESS-RELEASE — Impact 5/10
May 4, 2026
Press
Candel Therapeutics announced a conference call on May 15, 2026, to discuss extended follow-up data from the Phase 3 tri
Impact 3/10
Mar 31, 2026
Insider
Manning Paul B sold 4,618 shares
Director @ $4.11 ($19.0K)
Mar 31, 2026
Insider
PAPA JOSEPH C sold 2,795 shares
Director @ $4.11 ($11.5K)
Mar 31, 2026
Insider
Loggia Nicoletta sold 779 shares
Director @ $4.11 ($3.2K)
Price Targets
$19.63
+147.5% upside
Strong Buy
Current $7.93
Low $9.00
Median $19.50
High $29.00
8 analysts
$9.00
$29.00
Analyst Ratings
4Strong Buy
9Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 20, 2026 | Cantor Fitzgerald | INITIATE | Overweight |
| Mar 18, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Mar 13, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Mar 13, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Dec 8, 2025 | Stephens & Co. | REITERATE | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.26 | $-0.26 — $-0.26 | -27% YoY | 1 |
| Next Q | $-0.26 | $-0.26 — $-0.26 | -15% YoY | 1 |
| Current FY | $-0.87 ▼ -13.4% | $-1.11 — $-0.74 | 0% YoY | 3 |
| Next FY | $0.22 ▲ +134.4% | $0.22 — $0.22 | 125% YoY | 1 |
Latest Reports
BULLISH
Press
8/10
Candel Therapeutics announced extended follow-up data from the phase 3 trial of aglatimagene (CAN-2409) in localized pro
May 15, 2026
NEUTRAL
8-K
4/10
Candel Therapeutics reported Q1 2026 results: net loss of $8.9M vs net income of $7.4M in Q1 2025, driven by higher R&D
May 14, 2026
NEUTRAL
PRESS-RELEASE
5/10
Candel Therapeutics reported Q1 2026 EPS of -$0.54, a 65.6% miss vs consensus of -$0.33, with no revenue. The company hi
May 14, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $46.5M | ADD |
| VANGUARD GROUP INC | $13.0M | ADD |
| MORGAN STANLEY | $757.3K | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $683.7K | ADD |
| TWO SIGMA INVESTMENTS, LP | $560.5K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 31, 2026 | Manning Paul | A | $19.0K |
| Mar 31, 2026 | PAPA JOSEPH | A | $11.5K |
| Mar 31, 2026 | Loggia Nicoletta | A | $3.2K |
| Feb 23, 2026 | Manning Paul | BUY | $3.0M |
Reddit Sentiment
64°
Warm
Bearish
Neutral
Bullish
7 institutional holders with $62.3M total value (11,018,775 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, MORGAN. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 8,234,299 | $46.5M | 74.7% | ADD +80.6% |
| 2 | VANGUARD GROUP INC | 2,305,060 | $13.0M | 20.9% | ADD +29.6% |
| 3 | MORGAN STANLEY | 134,031 | $757.3K | 1.2% | ADD +76.5% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 121,004 | $683.7K | 1.1% | ADD +35.6% |
| 5 | TWO SIGMA INVESTMENTS, LP | 99,200 | $560.5K | 0.9% | TRIM -27.1% |
| 6 | WELLS FARGO & COMPANY/MN | 73,899 | $417.5K | 0.7% | DOUBLED +180.9% |
| 7 | BANK OF AMERICA CORP /DE/ | 51,282 | $289.7K | 0.5% | TRIM -34.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 75,941 | 134,031 | +76.5% | $757.3K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 136,116 | 99,200 | -27.1% | $560.5K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 26,311 | 73,899 | +180.9% | $417.5K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 369,195 | 136,116 | -63.1% | $694.2K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 113,722 | 75,941 | -33.2% | $387.3K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 73,123 | 47,643 | -34.8% | $243.0K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 20,775 | 26,311 | +26.6% | $134.2K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 163,600 | 0 | -100.0% | $0.00 | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 369,195 | — | $1.9M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 163,600 | — | $827.8K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 83,880 | 113,772 | +35.6% | $575.7K | 2025-Q2 |
| MORGAN STANLEY | ADD | 62,476 | 113,722 | +82.0% | $575.4K | 2025-Q2 |
| UBS Group AG | TRIM | 187,094 | 82,167 | -56.1% | $415.8K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 179,251 | 73,123 | -59.2% | $370.0K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 13,589 | 20,775 | +52.9% | $105.1K | 2025-Q2 |
| FMR LLC | ADD | 3,923,599 | 7,085,316 | +80.6% | $40.0M | 2025-Q1 |
| VANGUARD GROUP INC | ADD | 1,339,150 | 1,736,104 | +29.6% | $9.8M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 687,749 | 328,036 | -52.3% | $1.9M | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 52,190 | 83,880 | +60.7% | $473.9K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 10,122 | 13,589 | +34.3% | $76.8K | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 110,701 | 687,749 | +521.3% | $6.0M | 2024-Q4 |
| UBS Group AG | DOUBLED | 9,446 | 156,806 | +1560.0% | $1.4M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 6,187 | 10,122 | +63.6% | $87.9K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 19,458 | 64,433 | +231.1% | $446.5K | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 46,777 | — | $324.2K | 2024-Q3 |
3 unique insiders with 1 transactions. Net insider value: $3.0M ($3.0M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | Manning Paul B | Director | A | 4,618 | $4.11 | $19.0K |
| Mar 31, 2026 | PAPA JOSEPH C | Director | A | 2,795 | $4.11 | $11.5K |
| Mar 31, 2026 | Loggia Nicoletta | Director | A | 779 | $4.11 | $3.2K |
| Feb 23, 2026 | Manning Paul B | Director | BUY | 550,458 | $5.45 | $3.0M |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 4.3/10.
NEUTRAL
8-K
4/10
Candel Therapeutics reported Q1 2026 results: net loss of $8.9M vs net income of $7.4M in Q1 2025, d
May 14, 2026
NEUTRAL
PRESS-RELEASE
5/10
Candel Therapeutics reported Q1 2026 EPS of -$0.54, a 65.6% miss vs consensus of -$0.33, with no rev
May 14, 2026
NEUTRAL
8-K
4/10
Analysis based on filing metadata only — document content was unavailable. The 8-K indicates a mater
Mar 12, 2026
BULLISH
8/10
Candel Therapeutics announced extended follow-up data from the phase 3 trial of aglatimagene (CAN-24
May 15, 2026
NEUTRAL
3/10
Candel Therapeutics announced a conference call on May 15, 2026, to discuss extended follow-up data
May 4, 2026
NEUTRAL
3/10
Candel Therapeutics entered into a commercialization agreement with EVERSANA to support the potentia
Apr 29, 2026
BULLISH
8/10
Candel Therapeutics released updated Phase 2a data for its immunotherapy aglatimagene (CAN-2409) in
Mar 17, 2026
MIXED
6/10
Candel Therapeutics reported Q4 and full-year 2025 financial results, highlighting a significant inc
Mar 12, 2026
Current analyst consensus: Strong Buy (87% buy). Based on 15 analysts: 4 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$19.63 mean target
+147.5% upside
Strong Buy (1.22)
$9.00 Low
$29.00 High
| Metric | Value |
|---|---|
| Current Price | $7.93 |
| Target Low | $9.00 |
| Target Mean | $19.63 |
| Target Median | $19.50 |
| Target High | $29.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.22) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.26 | $-0.26 | $-0.26 | -27.5% | — | — | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.26 | $-0.26 | $-0.26 | -14.9% | — | — | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.87 | $-1.11 | $-0.74 | 0.3% | -13.4% | — | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$0.22 | $0.22 | $0.22 | 125.2% | +134.4% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.260 | |
| 7d ago | $0.000 | -0.260 |
| 30d ago | $0.000 | -0.260 |
| 60d ago | $0.000 | -0.260 |
| 90d ago | $0.000 | -0.260 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 20, 2026 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Mar 18, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 13, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 13, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Dec 8, 2025 | Stephens & Co. | REITERATE | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 4 | 9 | 2 | 0 | 0 | 87% | |
| Apr 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Mar 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Jan 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
64°
Warm
Bearish
Neutral
Bullish
7 mentions
3 bullish
0 bearish
7 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 8, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 8, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 8, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 20, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 20, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
CADL - CANDEL THERAUPETICS
▲ 1
💬 1
⚡ 0.5
CADL - CANDEL THERAUPETICS
▲ 1
💬 1
⚡ 0.5
May 15, 2026
fda
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
<p align="justify">NEEDHAM, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-sta
May 14, 2026
earnings
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
<p align="justify">NEEDHAM, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-sta
May 13, 2026
other
Candel Therapeutics to Present at Upcoming Investor Conferences
<p align="justify">NEEDHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-st
May 13, 2026
earnings_calendar
CADL Q1 2026 Earnings Scheduled — 2026-05-13
May 13, 2026
short_volume
Short Volume: CADL — 55.9% short (0.4M / 0.8M)
Short: 443,829 | Exempt: 6,807 | TRF Vol: 793,953 | Short Ratio: 55.9% | Off-exchange volume (dark pool + OTC)
May 11, 2026
earnings_calendar
CADL Q1 2026 Earnings Scheduled — 2026-05-11
May 11, 2026
short_volume
Short Volume: CADL — 59.1% short (1.0M / 1.7M)
Short: 1,016,312 | Exempt: 4,644 | TRF Vol: 1,720,323 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
CADL Q1 2026 Earnings Scheduled — 2026-05-07
May 5, 2026
short_volume
Short Volume: CADL — 61.6% short (0.8M / 1.3M)
Short: 808,906 | Exempt: 29,474 | TRF Vol: 1,312,834 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)
May 4, 2026
fda
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
<p align="justify">NEEDHAM, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-sta
May 1, 2026
other
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">NEEDHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-sta
Apr 29, 2026
contract
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
<p align="left"><em>EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following pl
Apr 16, 2026
short_volume
Short Volume: CADL — 76.3% short (0.5M / 0.7M)
Short: 530,584 | Exempt: 3,000 | TRF Vol: 695,408 | Short Ratio: 76.3% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
short_volume
Short Volume: CADL — 72.4% short (0.4M / 0.5M)
Short: 365,613 | Exempt: 358 | TRF Vol: 505,166 | Short Ratio: 72.4% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
short_volume
Short Volume: CADL — 58.5% short (0.4M / 0.7M)
Short: 432,985 | Exempt: 0 | TRF Vol: 740,601 | Short Ratio: 58.5% | Off-exchange volume (dark pool + OTC)